Thus, ziv-aflibercept is now FDA approved for second-line use in

Thus, ziv-aflibercept is now FDA approved for second-line use in combination with FOLFIRI or irinotecan in patients with disease progression on oxaliplatin. There are no studies in surgical patients as of yet. Another oral agent, regorafenib, has also been investigated in the treatment of mCRC. Regorafenib inhibits multiple tyrosine kinases and possesses anti-angiogenic properties, specifically targeting VEGFR1-3, the angiopoietin Inhibitors,research,lifescience,medical receptor TIE2, RAF, PDGFR, fibroblast growth factor

receptor (FGFR), as well as KIT and RET (74,75). In the multi-national phase III CORRECT trial, patients with mCRC who had find more progressed on standard therapy were randomized to regorafenib or best supportive therapy with a primary endpoint of OS. Patients who received regorafenib had improved OS (median, 6.4 vs. 5 mos, respectively) (34). Therefore,

regorafenib is now indicated as a single agent in patients with mCRC refractory to chemotherapy. Currently there is no data in surgical patients; therefore, retrospective reports and prospective Inhibitors,research,lifescience,medical trials will help determine the role and safety of these agents in surgical Inhibitors,research,lifescience,medical patients with CRLM. Summary Great advances have been made in the management of patients with mCRC in the past three decades. Without treatment, patients with CRLM had a life expectancy of 4.5-12 months (76,77). The prognosis of patients with metastatic colorectal cancer of the liver has improved significantly over the past decade. Surgical resection of CRLM is still considered the only curative option and advances in surgical techniques and technology have increased the rates of patients with CRLM who may undergo Inhibitors,research,lifescience,medical hepatic resection. However, the management of CRLM mandates a multi-disciplinary effort because of the complexity of liver surgery and the tremendous advances in targeted therapies. Acknowledgements Disclosure: The authors Inhibitors,research,lifescience,medical declare no conflict of interest.
This is a retrospective study of patients in Caritas Medical Center (CMC), a hospital

serving mainly the Sham Shui Po district, Hong Kong Special Administration Region. The pathology database of CMC was searched for patients with the diagnosis of “MALT lymphoma” or “EMZBL-MALT” in stomach made between 1st July 1997 and 30th June 2009. Totally 30 subjects were included in this study. Clinical data were collected until the time of death (if applicable), the last date of attendance for those defaulted follow-up, or 30th June 2009, Vasopressin Receptor whichever came earlier. Diagnosis of EMZBL-MALT was made on the basis of histological and immunophenotypic analysis of gastric biopsies, and supplemented by molecular study using polymerase chain reaction to demonstrate clonal proliferation in equivocal cases. Helicobacter status (HP or H. Heilmanni), at time of diagnosis and after antibacterial therapy, was determined by histopathologic examination of gastric biopsies in all subjects.

This entry was posted in Antibody. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>